Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-22-002530
Filing Date
2022-08-24
Accepted
2022-08-24 16:20:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO THE SCHEDULE 13D sc13da213392003_08242022.htm SC 13D/A 72309
2 LETTER TO THE BOARD OF DIRECTORS ex991to13da213392003_082422.htm EX-99.1 6723
  Complete submission text file 0000921895-22-002530.txt   80641
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89959 | Film No.: 221191807
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2261 MARKET STREET #4307 SAN FRANCISCO CA 94114
Business Address 2261 MARKET STREET #4307 SAN FRANCISCO CA 94114 4158571965
Funicular Funds, LP (Filed by) CIK: 0001937147 (see all company filings)

EIN.: 882460308 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A